1. Summary Results of 17,000 Cases in Russian Literature c1985
Percentage Success Rate by Category

 

Circulatory 82%
Musculoskeletal 79%
Respiratory 84%
Digestive 93%
GU 89%
Ob-Gyn 78%
Nervous 81%
ENT 82%
Eye 93%
Dental 91%
Dermatological 68%
CA Palliative 80%
Misc 81%
2. Summary of Russian SCENAR results
published by Yori Gorfinkle, MD. Taganrog, Russia
Percent cured 84.91%
Percent Improved 94.75%
Average Treatments 12
Average total time (hours) 4.06
Total number of cases 17,309

The tables below indicate the effectiveness of the SCENAR in a wide range of medical conditions. Individual results may vary.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Details:

Diseases of the Circulation System
                
 
# Patients
Complete Cure
Significant Improvement
Moderate Improvement
Slight Improvement
No Result
% Cured
% Improved
Transient dytonia of blood vessels
682
614
38
10
12
8
90.03
98.83
Essential hypertension
318
261
13
22
8
14
82.08
95.60
Angina pextoris
228
138
42
8
13
14
60.53
88.16
Acute myocadial infarction
31
22
4
3
1
1
70.97
96.77
Sudden cardiac arrest
16
12
0
0
0
4
75.00
75.00
Acute heart failure
48
47
0
0
0
1
97.92
97.92
Ischemic heart disease
92
2
69
4
14
4
2.17
95.65
Cardialgia NOS
104
99
1
1
1
2
95.19
98.08
Hemorrhoids
408
391
14
1
1
1
95.83
99.75
Totals
1245
1586
180
49
50
62
72.46
93.37

 

 

Diseases of Digestive System                
 
# Patients
Complete Cure
Significant Improvement
Moderate Improvement
Slight Improvement
No Result
% Cured
% Improved
Gastritis and duodenitis
1,018
1002
12
1
1
2
98.43
99.80
Gastric and Duodenal Ulcers
341
228
13
26
2
12
66.86
78.89
Enteritis (mainly non-infectious)
182
182
0
0
0
0
100
100
Colitis
302
263
20
10
3
6
87.09
98.01
Cholecystitis
218
145
6
10
3
4
66.51
75.23
Hepatitis/Hepatic Failure
48
47
0
0
0
1
97.92
97.92
Pancreatitis (Acute and Chronic)
63
63
0
0
0
0
100
100
Totals
2,172
1,930
51
47
9
25
88.12
92.84

 

 

Diseases of the Ear                
 
# Patients
Complete Cure
Significant Improvement
Moderate Improvement
Slight Improvement
No Result
% Cured
% Improved
Otitis
144
144
0
0
0
0
100
100
Hearing Loss
85
68
11
4
0
2
80.00
97.65
Abnormal auditory perception
116
98
4
2
4
8
84,48
93.10
Totals
345
310
15
6
4
10
89.86
97.10

 

 

Diseases & Trauma of Musculoskeletal System                
 
# Patients
Complete Cure
Significant Improvement
Moderate Improvement
Slight Improvement
No Result
% Cured
% Improved
Arthropathies (arthritis, arthrosis, etc.)
1,238
753
280
114
61
30
60.82
97.58
Dorsopathies (deformations, spondylosis)
2,352
2,048
252
35
17
2
87.07
100
Radiculopathy (trapped nerve)
1,820
1,670
102
40
6
2
91.76
99.89
Neuralgia (cervicalgia, lumbago, sciatica)
605
582
17
6
0
0
96.20
100
Myositis
840
839
0
0
0
1
99.88
99.88
Ligament strain
108
108
0
0
0
0
100
100
Superficial injury of soft tissues
325
325
0
0
0
0
100
100
Unknown pain (soft tissues and bones)
32
28
1
1
1
1
87.50
96.88
Totals
7,320
6,353
652
196
85
36
90.40
99.28

 

 

Diseases of Respiratory System                
 
# Patients
Complete Cure
Significant Improvement
Moderate Improvement
Slight Improvement
No Result
% Cured
% Improved
Acute nasopharyngitis (common cold)
608
601
6
0
0
1
98.85
99.84
Acute upper respiratory viral infection
345
345
0
0
0
0
100
100
Influenza
104
104
0
0
0
0
100
100
Acute Tonsilititis and pharyngitis
328
314
14
0
0
0
95.73
100
Acute Sinusitis
221
218
3
0
0
0
98.64
100
Acute Laryngitis and traceitis
402
380
18
2
0
0
94.53
99.50
Acute Bronchitis
615
562
24
15
7
7
91.38
98.86
Pneumonia
138
116
14
2
3
3
84.06
97.83
Asthma
82
31
15
22
7
7
37.80
91.46
Acute respiratory failure
15
14
0
0
0
1
93.33
93.33
Acute edema of the lung
12
11
0
0
0
1
91.67
91.67
Pleurisy
38
22
2
1
1
1
86.84
97.37
Totals
2,908
2,729
96
42
18
21
89.40
97.49

 

 

Urogenital Diseases (Female)                
 
# Patients
Complete Cure
Significant Improvement
Moderate Improvement
Slight Improvement
No Result
% Cured
% Improved
Mastopathy
264
220
8
16
3
18
83.33
93.56
Acute Mastitis
88
88
0
0
0
0
100
100
Salpingitis/ovarian cyst
608
604
1
1
1
1
99.34
99.84
Endometriosis
126
98
4
10
7
7
77.78
94.44
Fibromyoma of uterus
201
116
38
21
3
23
57.71
88.56
Erosion of cervix uteri
120
119
0
0
0
1
99.71
99.71
Dysmernorrea (menstrual cycle disorders)
180
112
30
12
0
26
62.22
85.56
Female infertility
86
63
0
0
0
23
73.26
73.26
Frigidity
38
18
6
7
1
6
47.37
84.21
Totals
1,447
1,438
87
67
15
105
77.11
90.63

 

 

Urogenital Diseases (Male)                
 
# Patients
Complete Cure
Significant Improvement
Moderate Improvement
Slight Improvement
No Result
% Cured
% Improved
Pyelonephritis (Acute and Chronic)
402
384
4
7
3
4
95.52
99.00
Urinary calculi
161
140
7
6
5
3
86.96
98.14
Cystitis
208
207
0
0
0
1
99.52
99.52
Urethritis
24
22
1
0
0
1
91.67
95.83
Prostatitis (Acute and Chronic)
605
602
3
0
0
1
99.50
100
Hyperplasia of prostate
88
63
7
3
8
7
71.59
92.05
Male infertility
62
44
0
0
0
18
70.97
70.97
Impotence
322
269
14
0
0
48
80.75
85.09
Totals
1,872
1,722
36
16
16
83
87.06
92.58

 

 

In Europe and USA the SCENAR is registered as the following device:

Europe:
The SCENAR 97.4+ has been awarded the CE mark and complies with the European Medical Directive (93/42/EEC). This documentation states it is:

A device for monitoring, treating and alleviating non-specific disease, injury or handicap by supplying low-level electrical energy to the body system in a form that may reduce pain, oedema and inflammation in a manner that allows the natural resources of that body to restore homeostasis more rapidly than if it were left alone......(by) electrical action on the skin surface activating tissues in the "somatic and autonomous" nervous system...(leading to) the possibility of a therapeutic effect in addition to mediating pain by the production of endorphins.
In simple terms Scenar Treatment is currently permitted to claim positive efficacy for pain relief and pain management for to use in all countries in the European Union, and is a 'safe device'.

USA:
SCENAR 97.4+ Biofeedback-controlled. Regulated by the US FDA under 21 CFR 882.5050, Generic Name: Device, Biofeedback, Product Code HCC, Class II exempt from 510(K) pre-market notification according to FDA Notice FR21ja98-84 as a battery-powered, professional use device for relaxation training and muscle education.A Class III FDA approval is pending. Prior to that approval, the manufacturer can only promote use for above in the US.